The Effect of Rosuvastatin on Prevention of Contrast-Induced Acute Kidney Injury in Patients with Chronic Kidney Disease

Abstract

Background: Contrast-induced acute kidney injury (CI-AKI) is an important issue in patients who are candidate for using contrast media in order to do diagnostic and therapeutic imagining. This study aimed to investigate the effect of rosuvastatin on the development of contrast-induced acute kidney injury in patients with chronic kidney disease performing computed tomography (CT) scan with contrast media. Methods: In this clinical trial study, 402 patients with chronic kidney disease who underwent CT scan with contrast in Alzahra hospital, Isfahan, Iran, during the years 2018-2019 were studied. Patients were divided into two groups, patients in the first group received 20 mg rosuvastatin 24 hours prior to CT scan and 10 mg rosuvastatin tablets daily for two consecutive days. The second group received the placebo. Findings: There was a significant difference in creatinine and glomerular filtration rate (eGFR) after CT scan (P < 0.050). The mean of creatinine was lower, and the mean of eGFR was higher in the intervention group than placebo after the intervention (P < 0.050). The frequency of contrast-induced acute kidney injury in the intervention group was 1%, and in the placebo group was 4% (P = 0.059). Conclusion: Rosuvastatin can reduce the risk of contrast-induced acute kidney injury after using contrast media, including increase in creatinine, and decrease in eGFR.

Keywords

• acute kidney injury
• chronic kidney disease
• contrast agent
• glomerular filtration rate
• creatinine